



# Press Release

## **ProStrakan Group plc**

### **Board Change**

Galashiels, Scotland, 28 January 2008 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that Alan Walker, V.P. Global Commercial Operations, has resigned from his position on the Board of Directors of ProStrakan and will be leaving the Company in order to pursue other interests.

Alan joined ProStrakan, in 2001 following an international career in the pharmaceuticals industry and joined the Board in 2006. At ProStrakan he was responsible for the sales and marketing of ProStrakan's products across Europe and for business development. His executive responsibilities will be assumed by Mark Webster, V.P. Global Strategic Marketing & North America, Abid Karim, Head of European Commercial Operations, and Dr Tom Stratford, Head of Global Business Development, who will each report to Chief Executive, Dr Wilson Totten.

Commenting on the announcement, Peter Allen, Chairman, said:

“Alan’s contribution to his role and to the Board has been immeasurable and, on behalf of the Board, I would like to thank him for this significant contribution to ProStrakan and to wish him well with his future plans.”

Alan Walker said:

“In seven years I have witnessed ProStrakan blossom into a fully-fledged international pharmaceutical company and I’m proud to have played a part in that growth. As ProStrakan enters the next phase in its development, I wish the company and all its people success.”

Ends

**For more information on this announcement, please contact:**

**ProStrakan** +44 (0)1896 664000  
Dr Wilson Totten, Chief Executive  
Paul Garvey, Chief Financial Officer  
Callum Spreng, Corporate Comms Director

**Financial Dynamics** +44 (0)20 7831 3113  
David Yates / Ben Brewerton

**Trout Group** (for US investor enquiries)  
Gitanjali Jain (646) 378-2949

**ProStrakan**

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries.  
**[www.prostrakan.com](http://www.prostrakan.com)**